-
Increasing unusual call option volume: ECH MOD ZSL JBS BXSL GOSS TRX AQST IRE BRBR
-
Gossamer Bio Inc. (GOSS) files mixed shelf
-
Gossamer Bio (GOSS) Reiterated at Overweight by Cantor Fitzgerald: Phase 3 Readout in Feb
-
H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
-
Gossamer Bio's (GOSS) Seralitinib Data Likely Comes Out by Feb - Cantor Fitzgerald
-
Gossamer Bio Inc. (GOSS) Misses Q3 EPS by 2c
-
Goldman Sachs Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
-
H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
-
This name is facing a 'major underappreciated data catalyst' says UBS
-
Increasing unusual call option volume: SPHR SNPS GOSS OPAD SWBI SNDK LDI HIVE PACS RZLV PSQH
-
Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
-
UBS Upgrades Gossamer Bio Inc. (GOSS) to Buy
-
H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
-
Gossamer Bio Inc. (GOSS) Tops Q1 EPS by 3c
-
H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
-
Gossamer Bio Inc. (GOSS) Tops Q4 EPS by 2c
-
Gossamer Bio (GOSS) Presented Clinical and Preclinical Data
-
Piper Sandler Explores Direct and Indirect Catalysts for Selected Biotechnology Companies
-
Gossamer Bio Inc. (GOSS) Tops Q3 EPS by 1c
-
H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
-
Piper Sandler Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
H.C. Wainwright Reiterates Buy Rating on Gossamer Bio Inc. (GOSS)
-
Gossamer Bio Inc. (GOSS) Misses Q2 EPS by 29c
-
Piper Sandler Reiterates Overweight Rating on Gossamer Bio Inc. (GOSS)

